ChromaDex Announces Second Human Clinical Trial

Publishing & Media

Share Tweet

ChromaDex Announces Second Human Clinical Trial

ChromaDex Inc. (OTCQB: CDXC) saw its share volume soar on May 20th with 224,975 shares exchanging hands, significantly higher than its three month daily average volume of 143,835 shares. 

This jump in volume comes after ChromaDex, a company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced the initiation of the second human clinical study for PURENERGY(R), its patented caffeine ingredient.

PURENERGY(R) is an innovative patented caffeine ingredient that is a cocrystal combination of caffeine and ChromaDex's patented pTeroPure(R) pterostilbene.  The combination forms a unique crystalline structure that has superior benefits as compared to caffeine alone. Recently, caffeinated energy products have come under increased regulatory and political scrutiny because of the possible risks associated with consuming high amounts of caffeine.  PURENERGY(R) offers product formulators a unique solution to reduce total caffeine content while optimizing the consumer experience - as well as delivering the benefits of pTeroPure(R).

Frank L. Jaksch Jr., CEO of ChromaDex, commented, "This study will provide additional valuable insight into the benefits of PURENERGY(R), building on our previous successful human study.  We have already had tremendous interest in PURENERGY(R) and anticipate seeing numerous retail products launched in 2014 and beyond that incorporate PURENERGY(R) as a compelling alternative ingredient to caffeine alone."

Results from the first study conducted in 2013 showed that PURENERGY(R) delivers 30 percent more caffeine to the bloodstream and also extends the half-life of caffeine by 25 percent as compared to caffeine alone.

CDXC closed at $1.55 on May 20th, 6.9% higher than its previous close of $1.45. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:


Nuvilex Sees Share Volume Drop

Nuvilex, Inc. (OTCQB: NVLX) saw its share volume continue its downward trend on May 20th with 3,037,761 shares exchanging hands, more than three times lower than its three month daily average volume of 10,686,585 shares.

Nuvilex is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced inoperable pancreatic cancer, and diabetes are being built.

Nuvilex's treatment for pancreatic cancer involves the widely used anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. Nuvilex is also working towards clinical trials associated with the symptoms of advanced pancreatic cancer and other abdominal cancers.

Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast, and prostate that affect hundreds of thousands of individuals worldwide every year.

NVLX closed the day on May 20th at $.2987. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:


Elite Pharmaceuticals Announced First Dosing In Bioequivalence Study

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) saw its share volume continue to plummet on May 20th with 1,586,379 shares exchanging hands, three times lower than its three month daily average volume of 4,710,870 shares.

Elite Pharmaceuticals announced on Monday the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-202, an undisclosed opioid abuse deterrent product, utilizing Elite's proprietary pharmacological abuse deterrent technology.

"Abuse of prescription narcotics is a serious problem in our society and we are pleased to be working with new approaches to help address this problem," said Nasrat Hakim, President and CEO of Elite. "I have described my vision for a range of abuse deterrent products that use Elite's proprietary pharmacological abuse deterrent technology and I am pleased to announce initiation of this pivotal study for ELI-202, one of several abuse deterrent products currently under development by Elite. Our plans include completing bioequivalency studies for a third abuse deterrent product and doing In Vitro Lab Abuse Studies and human abuse studies for the first product in 2014. I expect Elite to file an NDA for its first abuse deterrent product with the FDA by year's end."

Elite's development pipeline includes a range of opioid products utilizing Elite's proprietary abuse deterrent technology. Elite is currently working on five such abuse deterrent products.

ELTP closed at $.415 on May 20th, 3.49% lower than its previous close of $.43. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:


ABOUT US: issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:



Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.